SB-121
Autism Spectrum Disorder (with GI comorbidities)
Phase 1bActive
Key Facts
Indication
Autism Spectrum Disorder (with GI comorbidities)
Phase
Phase 1b
Status
Active
Company
About Scioto Biosciences
Scioto Biosciences is a private, preclinical-stage biotech pioneering a novel approach to live bacterial therapeutics (LBTs). The company's proprietary Activated Bacterial Therapeutics (ABT) platform aims to overcome key delivery challenges by utilizing bacterial biofilms to enhance persistence and activity in the gastrointestinal tract. Its lead program, SB-121, has completed a Phase Ib trial in Autism Spectrum Disorder (ASD), demonstrating initial clinical validation of its platform. The company is targeting significant unmet medical needs in neurodevelopmental and GI conditions, positioning itself at the intersection of the microbiome and gut-brain axis fields.
View full company profile